These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31099410)

  • 21. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
    J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
    Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
    World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other?
    Dillman JR; Trout AT; Costello EN; Serai SD; Bramlage KS; Kohli R; Xanthakos SA
    AJR Am J Roentgenol; 2018 Jan; 210(1):166-174. PubMed ID: 29045180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits.
    Xie Y; Zhang H; Jin C; Wang X; Wang X; Chen J; Xu Y
    Magn Reson Imaging; 2018 May; 48():34-41. PubMed ID: 29278765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.
    Petäjä EM; Yki-Järvinen H
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.
    Hui SCN; So HK; Chan DFY; Wong SKH; Yeung DKW; Ng EKW; Chu WCW
    Eur J Radiol; 2018 Oct; 107():7-13. PubMed ID: 30292275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing mono-exponential, bi-exponential, and stretched-exponential diffusion-weighted MR imaging for stratifying non-alcoholic fatty liver disease in a rabbit model.
    Li C; Ye J; Prince M; Peng Y; Dou W; Shang S; Wu J; Luo X
    Eur Radiol; 2020 Nov; 30(11):6022-6032. PubMed ID: 32591883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
    PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH.
    De Rudder M; Bouzin C; Nachit M; Louvegny H; Vande Velde G; Julé Y; Leclercq IA
    Lab Invest; 2020 Jan; 100(1):147-160. PubMed ID: 31506634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease.
    Dasarathy J; Periyalwar P; Allampati S; Bhinder V; Hawkins C; Brandt P; Khiyami A; McCullough AJ; Dasarathy S
    Liver Int; 2014 Jul; 34(6):e118-27. PubMed ID: 24118743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
    Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
    Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
    Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.